Inve India ▾

Sigachi Industries share price & results

Sigachi Industries Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue98.3 ₹ crore−11.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin13.4 %−8.2 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit6.5 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity4.15 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-7.74 %−4.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-9.58 %−24.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 2 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

Sigachi Industries Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (0 achieved, 2 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growth>25% growth over the next 2 to 3 years
Call transcript, Q4 FY25 · 30 May 2025		Q4 FY25Q1 FY27:Historical promise that was missed in FY26. Not discussed.
Call transcript, Q1 FY27 · 13 Aug 2026		Missed
EBITDA Marginbeyond 25%
Call transcript, Q4 FY25 · 30 May 2025		Q4 FY25Q1 FY27:Management reiterated FY27 guidance of 18%, which is significantly below the original >25% target. Q1 margin was 13.6%. The promise remains significantly delayed.
Call transcript, Q1 FY27 · 13 Aug 2026		Delayed
Revenue from Cystic Fibrosis APIINR 250 crores after 12 months post-commercialization
Call transcript, Q3 FY26 · 14 Feb 2026		Q3 FY26Q1 FY27:Management stated that revenues from the cystic fibrosis product are expected by next year, indicating the project is progressing.
Call transcript, Q1 FY27 · 13 Aug 2026		On Track

Source: Inve Guidance Tracker for Sigachi Industries Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Sigachi Industries Limited's 17 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹26.16 +5.36% · +₹1.33

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −32.9% 1Y

₹20.0₹25.0₹30.0₹35.0₹40.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 24 Oct 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 29 May 2026Q1 FY27 — 13 Aug 2026

1Y: ₹39 on 24 Oct 2025 → ₹26.16. High ₹39 (24 Oct 2025), low ₹16.92 (30 Mar 2026).

Previous close
₹24.83
Market cap
₹949 Cr
52-week range
₹16.92 – ₹38.19
One year
−31.18%
Price to earnings (TTM to Jun 2026)
40.69×
Return on equity (TTM to Jun 2026)
4.15%

Overview

Symbol
NSE:SIGACHI
Exchange
NSE
Currency
INR

How the price took the results

close before → close after

Q1 FY27
+4.7%
13 Aug
Q4 FY26
+4.9%
30 May
Q3 FY26
−3.0%
14 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sigachi Industries Limited

Free account: one company. Everything above stays public.

Write why you follow Sigachi Industries Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sigachi Industries Limited

Guides on how to read this kind of business and the numbers that matter.